Grannus Therapeutics, Inc.
Indianapolis, IN
- UEI
- CKYDPT5R18Z8
- CAGE
- 8J1H2
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 7341 N Washington Blvd, Indianapolis, IN 46240, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| New treatments for glaucoma | National Eye Institute (NIH) | $1,039,686 | |
| Development of HSP90 beta-selective inhibitors as safer anti-cancer agents | National Cancer Institute (NIH) | $233,195 |
Quick answers
Is Grannus Therapeutics, Inc. registered in SAM.gov?
Yes. Grannus Therapeutics, Inc.'s SAM.gov registration is active through June 16, 2027.
What is Grannus Therapeutics, Inc.'s most recent federal award?
Grannus Therapeutics, Inc.'s most recent federal grant award is New treatments for glaucoma (R41EY033263), from National Eye Institute (NIH), on September 1, 2021.
On GovTribe
See Grannus Therapeutics, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors